Nevertheless,
Valneva climbs stock market after:
Illustration shows Valneva logo
Valneva flies away on Tuesday on the Paris Stock Exchange after having published half -yearly results deemed “solid”, carried in particular by the sales of its Ixiaro/Jespect vaccine. Consequently,
Around 8:30 am GMT, the title Valneva earned 9.6% after climbing up to more than 13% earlier in session, while the SBF120 increased by 0.47% at the same time. However,
The French biotechnology company saw its turnover increase by 37.8% in the first half, to 97.6 million euros, but recorded an EBITDA adjusted to -6 million euros, against a profit of 56.2 million euros a year ago. However,
The semester 2024 had benefited from an exceptional product from the valneva climbs stock market after sale of the priority review voucher (PRV) 1. underlines Valneva in a press release.
The performance in the first half was notably supported by sales of the Japanese encephalitis vaccine Ixiaro/Jespect. which increased by 30.6% to 54.7 million euros.
Kempen analysts qualified these results as “solid”, welcoming continuous sales growth.
“The company has confirmed the calendar of the Lyme disease vaccine program,” they also stress.
Valneva has also confirmed its financial prospects as announced in May. and said it was rejecting a turnover between 180 million and 190 million euros for 2025.
(Written by Coralie Lamarque. Mathias de Rozario, edited by Augustin Turpin and Blandine Hénault)
valneva climbs stock market after — Valneva climbs stock market after: Illustration shows Valneva logo Valneva flies away on Tuesday on the Paris Stock Exchange after having published half -yearly res.
Further reading: All owners can lower their property tax in just a few weeks – Meta takes off and enchant Wall Street despite its expenses in AI – The case which ruined dozens of franchisees in Morocco – The United States is preparing a nuclear reactor on the moon – Dubuc Motors sentenced $ 145,000 in fines: end of an eight -year saga.
